SOUTH PLAINFIELD, N.J., March 31 /PRNewswire/ -- PTC Therapeutics, Inc.
today announced that the company has filed with the Securities and Exchange
Commission a registration statement relating to the proposed initial public
offering of shares of its common stock. All shares of the common stock to be
sold in the offering will be sold by PTC Therapeutics, Inc.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
Morgan Stanley & Co. Incorporated will act as sole book-runner and lead
manager, J.P. Morgan Securities Inc. will act as co-lead manager and Pacific
Growth Equities, LLC will act as co-manager in the offering.
A registration statement relating to these securities has been filed with
the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted prior to
the time the registration statement becomes effective. When available, a
preliminary prospectus may be obtained from Morgan Stanley & Co. Incorporated,
by emailing prospectus@morganstanley.com, or by contacting the prospectus
department at Morgan Stanley & Co. Incorporated, 1585 Broadway, New York, New
York 10036, by telephone at 212-761-6775.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development,
and commercialization of orally administered, proprietary small-molecule drugs
that target post-transcriptional control processes. Post-transcriptional
control processes regulate the rate and timing of protein production and are
of central importance to proper cellular function. PTC has assembled
proprietary technologies and extensive knowledge of post-transcriptional
control processes that it applies in its drug discovery and development
activities. PTC's current pipeline of clinical and preclinical product
candidates addresses multiple indications, including genetic disorders,
oncology, and infectious diseases.
SOURCE PTC Therapeutics, Inc.
 back to top
Related links:
http://www.ptcbio.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO
CONTACT:
Jane Baj of PTC Therapeutics, Inc.,
+1-908-222-7000, ext. 167, jbaj@ptcbio.com
|
